Arcus Biosciences, Inc. RCUS

RCUS Company Overview

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated immuno-oncology therapies for patients with cancer. The company operates within the biotechnology and pharmaceutical research industry, with a strategic emphasis on targeting key resistance pathways in tumor immunology. Arcus does not currently market approved products and generates limited revenue primarily from collaboration and licensing arrangements.

The company’s core value proposition is its rational, pathway-driven drug design platform, which aims to develop best-in-class or first-in-class small molecules and antibodies that can be combined across multiple tumor types. Arcus was founded in 2015 by experienced oncology drug developers and built its pipeline through in-house research rather than acquisitions, enabling tight integration of scientific strategy and clinical development.